Ondansetron Pharmc 4 mg/2 mL & 8 mg/4 mL Solution for injection
PDF Leaflet Revision Date: 13 March 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Management of nausea and vomiting induced by chemotherapy, radiotherapy, and post-operative.
Dosage (summary)
Adults: 8 mg IV/IM before treatment; max 16 mg for highly emetogenic chemotherapy. Elderly: max 8 mg IV.
Onset of Action / Duration
Onset: 30 mins, Duration: up to 24 hours
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; avoid breastfeeding.
Key Drug Interactions
- QT prolonging medicines
- Apomorphine
- Tramadol
Contraindications
- Hypersensitivity to ondansetron
- Pregnancy
- Congenital long QT syndrome
Common side effects
- Headache
- Dizziness
- Constipation
- Visual disturbances
Counselling Points
- Avoid driving until effects are known
- Monitor for signs of myocardial ischaemia
- Use contraception during treatment
Serious warnings
- QT prolongation risk
- Myocardial ischaemia
- Serotonin syndrome
Important Disclaimer
The Ondansetron Pharmc 4 mg/2 mL & 8 mg/4 mL Solution for injection professional information leaflet below is the property of Pharmacorp and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
